Mikko Välimäki has been appointed to Abomics’ Board of Directors, while Ari Hakkarainen has concluded his term. Välimäki brings extensive experience in technology companies, entrepreneurship, and international growth, strengthening the Board’s work in supporting the company’s long-term development.
Mikko Välimäki has been appointed as a new member of the Board of Directors of Abomics. At the same time, Ari Hakkarainen has concluded his term on the company’s Board.
Mikko Välimäki has a strong background in technology-driven business and board-level roles. An accomplished entrepreneur, he has co-founded and led as CEO several technology companies, including quantum computer manufacturer IQM Quantum Computers and software company Tuxera. Välimäki brings a strong track record of driving profitable global growth across Europe, Asia, and North America.
Välimäki holds a Doctor of Science degree from Aalto University and a Master of Laws degree from the University of Helsinki. His expertise in international business growth and strategic leadership brings valuable perspective to the work of the Abomics Board in supporting the company’s long-term development.
Abomics thanks Ari Hakkarainen for his significant contribution to the work of the Board and welcomes Mikko Välimäki to the Board of Directors of Abomics.
Abomics has appointed a new Lead Bioinformatician to deepen its expertise in genomics and pharmacogenetics. The role strengthens scientific capabilities behind clinically actionable solutions and supports the practical implementation of precision medicine in healthcare settings.
Abomics has renewed its ISO 13485:2016 certification, confirming that its pharmacogenetic reporting and clinical decision support solutions meet internationally recognized quality standards. The certification reinforces consistent, risk-based processes that support safe and reliable implementation.
MD Nora Nikander joins Abomics’ Medical Advisory team, bringing clinical experience from university hospital care and a strong focus on pharmacogenetics. Her expertise supports the development of practical, clinically relevant tools that enable safer, individualized prescribing in everyday healthcare.